Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 212 participants.
Also called NCT05373004
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 212 participants
- Sponsor
- Omar Tarek Elfarargi
- Registry
-
NCT05373004
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05373004. Randomized; double masking; primary purpose prevention. Start 2023-03 (anticipated); primary completion 2024-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
- Acronym
- SGLT2i VS ACEi
- Condition
- Diabetic Nephropathy Type 2
- Intervention (Drug)
- Empagliflozin 25 MG
- Intervention (Drug)
- Enalapril Maleate 20 mg
- Lead sponsor
- Omar Tarek Elfarargi
Record details
- Record id
cardio:ct-nct05373004- Content hash
45c78968da8945757344bf9de8bd372b57736d5fc32774e72df8a354d6f7469e